➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Dow
McKesson
Merck
McKinsey

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

LIALDA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Lialda patents expire, and when can generic versions of Lialda launch?

Lialda is a drug marketed by Takeda Pharms Usa and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in seventeen countries.

The generic ingredient in LIALDA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

US ANDA Litigation and Generic Entry Outlook for Lialda

A generic version of LIALDA was approved as mesalamine by PERRIGO ISRAEL on September 17th, 2004.

  Start Trial

Drug patent expirations by year for LIALDA
Drug Prices for LIALDA

See drug prices for LIALDA

Drug Sales Revenue Trends for LIALDA

See drug sales revenues for LIALDA

Recent Clinical Trials for LIALDA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NorthShore University HealthSystemPhase 2
ShirePhase 1
Shire Human Genetic Therapies, Inc.Phase 3

See all LIALDA clinical trials

Pharmacology for LIALDA
Drug ClassAminosalicylate
Paragraph IV (Patent) Challenges for LIALDA
Tradename Dosage Ingredient NDA Submissiondate
LIALDA TABLET, DELAYED RELEASE;ORAL mesalamine 022000 2009-12-16

US Patents and Regulatory Information for LIALDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa LIALDA mesalamine TABLET, DELAYED RELEASE;ORAL 022000-001 Jan 16, 2007 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Takeda Pharms Usa LIALDA mesalamine TABLET, DELAYED RELEASE;ORAL 022000-001 Jan 16, 2007 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Baxter
Dow
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.